Notable Analyst Upgrades and Downgrades for Week of November 22 2021


 

Upgrades:

 


Kimco Realty (NYSE:KIM) was upgraded by equities researchers at Evercore ISI to an "outperform" rating in a note issued to investors on Monday, The Fly reports.

KIM has been the topic of several other research reports. Capital One Financial raised Kimco Realty from an "equal weight" rating to an "overweight" rating and set a $26.00 target price on the stock in a research report on Monday, August 2nd. BTIG Research restated a "hold" rating on shares of Kimco Realty in a research note on Sunday, September 26th. Truist upped their price objective on Kimco Realty from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, August 30th. Truist Securities upped their target price on Kimco Realty from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, August 30th. Finally, Morgan Stanley upped their target price on Kimco Realty from $25.00 to $26.00 and gave the company an "overweight" rating in a research report on Thursday, August 19th. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $23.32.

KIM stock opened at $24.05 on Monday. Kimco Realty has a twelve month low of $14.03 and a twelve month high of $24.95. The stock has a market cap of $14.83 billion, a P/E ratio of 12.59, a PEG ratio of 2.11 and a beta of 1.50. The business's 50-day moving average price is $22.55 and its 200-day moving average price is $21.71. Read more …

 


Royal Gold (NASDAQ:RGLD) (TSE:RGL) was upgraded by research analysts at Bank of America from an "underperform" rating to a "neutral" rating in a report issued on Monday, The Fly reports.

RGLD has been the topic of a number of other research reports. TD Securities lowered their price objective on Royal Gold from $145.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, August 13th. Zacks Investment Research raised Royal Gold from a "sell" rating to a "hold" rating and set a $106.00 price objective on the stock in a report on Tuesday, October 26th. Raymond James set a $136.00 price objective on Royal Gold and gave the company an "outperform" rating in a report on Thursday, November 4th. BMO Capital Markets lifted their price objective on Royal Gold from $138.00 to $145.00 and gave the company a "market perform" rating in a report on Friday, August 13th. Finally, National Bank Financial lowered their price objective on Royal Gold from C$160.00 to C$155.00 and set a "sector perform" rating on the stock in a report on Friday, September 10th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Royal Gold has an average rating of "Hold" and an average price target of $136.03.

NASDAQ RGLD opened at $105.43 on Monday. The company has a quick ratio of 3.65, a current ratio of 3.85 and a debt-to-equity ratio of 0.04. Royal Gold has a 52-week low of $92.01 and a 52-week high of $129.69. The business's 50-day moving average price is $101.26 and its 200 day moving average price is $111.48. The firm has a market cap of $6.92 billion, a P/E ratio of 26.10, a P/E/G ratio of 2.67 and a beta of 0.64. Read more …

 


AbbVie (NYSE:ABBV) was upgraded by investment analysts at Societe Generale from a "hold" rating to a "buy" rating in a report issued on Tuesday, PriceTargets.com reports.

Several other analysts also recently weighed in on ABBV. Mizuho lifted their price target on shares of AbbVie from $128.00 to $131.00 and gave the company a "buy" rating in a research note on Monday, August 2nd. Argus increased their price target on AbbVie from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, August 5th. Truist Securities started coverage on AbbVie in a report on Tuesday, July 27th. They issued a "buy" rating and a $117.00 price objective for the company. Cowen upped their price objective on shares of AbbVie from $120.00 to $130.00 and gave the stock an "outperform" rating in a research note on Monday, August 23rd. Finally, Morgan Stanley raised their target price on shares of AbbVie from $116.00 to $124.00 and gave the company an "overweight" rating in a research report on Monday, November 1st. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $127.17.

ABBV stock traded up $3.23 during midday trading on Tuesday, reaching $118.88. The company's stock had a trading volume of 8,594,465 shares, compared to its average volume of 6,838,689. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.91 and a current ratio of 1.01. The stock has a fifty day simple moving average of $111.39 and a two-hundred day simple moving average of $113.87. AbbVie has a 1 year low of $101.55 and a 1 year high of $121.53. The firm has a market capitalization of $210.08 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 2.46 and a beta of 0.83. Read more …

 

 


Best Buy (NYSE:BBY) was upgraded by research analysts at Bank of America to a “buy” rating in a research report issued on Wednesday, The Fly reports.

Several other equities research analysts also recently weighed in on BBY. Wedbush raised Best Buy to a “buy” rating in a research report on Wednesday, August 25th. DA Davidson raised Best Buy to a “buy” rating in a research report on Wednesday, August 25th. Zacks Investment Research reaffirmed a “buy” rating on shares of Best Buy in a research report on Friday, September 10th. Jefferies Financial Group increased their price target on Best Buy from $136.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, August 25th. Finally, Citigroup restated a “buy” rating on shares of Best Buy in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $128.31. Read more …

 


Bank of Nova Scotia (NYSE:BNS) (TSE:BNS) was upgraded by equities researchers at Canaccord Genuity from a “hold” rating to a “buy” rating in a research note issued on Wednesday, The Fly reports.

Other equities analysts have also issued research reports about the stock. National Bank Financial increased their target price on shares of Bank of Nova Scotia from $84.00 to $86.00 and gave the company a “sector perform” rating in a report on Wednesday, August 25th. TD Securities reduced their target price on shares of Bank of Nova Scotia from C$90.00 to C$87.00 and set a “buy” rating on the stock in a report on Wednesday, August 25th. Veritas Investment Research reaffirmed a “buy” rating on shares of Bank of Nova Scotia in a report on Friday, November 12th. Royal Bank of Canada increased their target price on shares of Bank of Nova Scotia from C$86.00 to C$89.00 and gave the company an “outperform” rating in a report on Wednesday, August 25th. Finally, Zacks Investment Research cut shares of Bank of Nova Scotia from a “buy” rating to a “hold” rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Bank of Nova Scotia presently has an average rating of “Buy” and an average target price of $86.43. Read more …

 


Chevron (NYSE:CVX) was upgraded by stock analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating in a research note issued on Wednesday, The Fly reports.

A number of other research firms also recently issued reports on CVX. TheStreet upgraded shares of Chevron from a "c" rating to a "b-" rating in a research report on Friday, July 30th. Zacks Investment Research downgraded shares of Chevron from a "buy" rating to a "hold" rating and set a $100.00 target price for the company. in a research report on Tuesday, September 21st. Wells Fargo & Company increased their target price on shares of Chevron from $109.00 to $115.00 and gave the stock an "equal weight" rating in a research report on Monday, November 1st. DZ Bank downgraded shares of Chevron from a "buy" rating to a "hold" rating and set a $110.00 target price for the company. in a research report on Wednesday, August 4th. Finally, Morgan Stanley raised their price target on shares of Chevron from $149.00 to $155.00 and gave the company an "overweight" rating in a report on Friday, November 19th. Ten research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $120.65.

Chevron stock opened at $116.30 on Wednesday. The company has a 50 day moving average price of $108.83 and a 200 day moving average price of $104.82. Chevron has a 52 week low of $83.53 and a 52 week high of $118.08. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.28. The firm has a market capitalization of $224.19 billion, a price-to-earnings ratio of 22.45, a P/E/G ratio of 2.42 and a beta of 1.30. Read more …

 

 

 

Downgrades:

 


AstraZeneca (NASDAQ:AZN) was downgraded by stock analysts at Bryan, Garnier & Co to a “buy” rating in a research note issued to investors on Monday, The Fly reports.

Several other brokerages have also issued reports on AZN. SVB Leerink lifted their price target on AstraZeneca from $71.00 to $73.00 and gave the company an “outperform” rating in a research note on Monday, September 27th. JPMorgan Chase & Co. assumed coverage on AstraZeneca in a research note on Thursday, August 12th. They issued an “overweight” rating on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of AstraZeneca in a research note on Monday, October 11th. UBS Group restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 19th. Finally, Morgan Stanley restated an “overweight” rating on shares of AstraZeneca in a research report on Friday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $124.00. Read more …

 


Pembina Pipeline (NYSE:PBA) (TSE:PPL) was downgraded by equities researchers at CIBC from an "outperform" rating to a "neutral" rating in a note issued to investors on Monday, The Fly reports.

A number of other analysts also recently commented on the company. TD Securities upped their price objective on Pembina Pipeline from C$43.00 to C$45.00 and gave the stock a "buy" rating in a report on Monday, November 8th. Royal Bank of Canada upped their price objective on Pembina Pipeline from C$42.00 to C$48.00 and gave the stock an "outperform" rating in a report on Monday, August 9th. Scotiabank upped their price objective on Pembina Pipeline from C$42.00 to C$43.00 and gave the stock a "sector perform" rating in a report on Friday, November 5th. Credit Suisse Group initiated coverage on Pembina Pipeline in a report on Wednesday, August 18th. They set a "neutral" rating for the company. Finally, BMO Capital Markets initiated coverage on shares of Pembina Pipeline in a research report on Wednesday, July 28th. They set a "market perform" rating for the company. One analyst has rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $40.40.

Shares of NYSE:PBA traded down $1.03 during trading on Monday, hitting $31.87. 81,796 shares of the stock were exchanged, compared to its average volume of 1,108,605. The company has a fifty day moving average price of $32.77 and a two-hundred day moving average price of $32.19. The company has a market cap of $17.54 billion, a PE ratio of -132.79, a P/E/G ratio of 5.35 and a beta of 1.43. The company has a current ratio of 0.54, a quick ratio of 0.52 and a debt-to-equity ratio of 0.84. Pembina Pipeline has a 12-month low of $23.48 and a 12-month high of $34.73. Read more …

 


Royal Bank of Canada (NYSE:RY) (TSE:RY) was downgraded by investment analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research note issued to investors on Monday, The Fly reports.

Several other analysts have also recently weighed in on RY. Desjardins lifted their price objective on shares of Royal Bank of Canada from C$138.00 to C$141.00 and gave the stock a “buy” rating in a research note on Friday, August 27th. Zacks Investment Research cut shares of Royal Bank of Canada from a “buy” rating to a “hold” rating in a research note on Saturday, November 13th. Scotiabank lifted their price objective on shares of Royal Bank of Canada from C$144.00 to C$148.00 in a research note on Tuesday, August 17th. Fundamental Research lifted their price objective on shares of Royal Bank of Canada from $127.27 to $143.76 and gave the stock a “buy” rating in a research note on Wednesday, September 1st. Finally, Credit Suisse Group boosted their target price on shares of Royal Bank of Canada from C$135.00 to C$140.00 and gave the company an “outperform” rating in a research report on Thursday, August 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $134.48. Read more …

 

 


Ventas (NYSE:VTR) was downgraded by equities researchers at Sumitomo Mitsui Financial Group from an "outperform" rating to a "neutral" rating in a report issued on Monday, Price Targets.com reports. They currently have a $55.00 price objective on the real estate investment trust's stock. Sumitomo Mitsui Financial Group's price target indicates a potential upside of 7.11% from the stock's current price.

Other equities analysts also recently issued reports about the company. Capital One Financial restated an "equal weight" rating on shares of Ventas in a report on Friday, November 5th. Raymond James upgraded Ventas from an "outperform" rating to a "strong-buy" rating and increased their target price for the company from $65.00 to $67.00 in a research note on Thursday, September 23rd. BMO Capital Markets upgraded Ventas from an "underperform" rating to a "market perform" rating and set a $60.00 target price for the company in a research note on Thursday, August 26th. Deutsche Bank Aktiengesellschaft upgraded Ventas from a "hold" rating to a "buy" rating and increased their target price for the company from $61.00 to $66.00 in a research note on Tuesday, September 7th. Finally, Morgan Stanley started coverage on Ventas in a research note on Monday, October 4th. They issued an "equal weight" rating and a $60.00 target price for the company. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $59.24.

Ventas stock opened at $51.35 on Monday. The stock's 50-day moving average is $55.15 and its 200-day moving average is $56.34. The company has a market cap of $20.50 billion, a price-to-earnings ratio of 96.89, a price-to-earnings-growth ratio of 4.94 and a beta of 1.17. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.59 and a quick ratio of 0.71. Ventas has a 12 month low of $45.40 and a 12 month high of $61.09. Read more …

 


National Bank of Canada (TSE:NA) was downgraded by research analysts at Scotiabank to a “hold” rating in a report issued on Tuesday, TipRanks reports. They presently have a C$113.00 target price on the financial services provider’s stock. Scotiabank’s price target points to a potential upside of 7.38% from the company’s previous close.

NA has been the topic of several other reports. Canaccord Genuity boosted their target price on National Bank of Canada from C$101.00 to C$103.50 and gave the stock a “hold” rating in a report on Thursday, August 26th. Barclays cut National Bank of Canada to a “sell” rating and set a C$100.00 target price on the stock. in a report on Monday, November 15th. BMO Capital Markets boosted their target price on National Bank of Canada from C$101.00 to C$104.00 and gave the stock an “outperform” rating in a report on Thursday, August 26th. Credit Suisse Group restated a “neutral” rating on shares of National Bank of Canada in a report on Thursday, September 2nd. Finally, Cormark lifted their price target on shares of National Bank of Canada from C$109.00 to C$112.00 and gave the company a “buy” rating in a research report on Thursday, August 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of C$100.23. Read more …

 

Comments

Popular posts from this blog

The 12 Best Financial Stocks to Buy for 2022

The 12 Best REITs to Buy for 2022

2 Bargain Stocks to Thrive in 2022

Raytheon Technologies: America's Next Top Aerospace Company?

7 Boring Stocks to Buy to Protect Against the Speculative Fallout

Realty Income Corp: 4.1%-Yielder Raises Dividend for 96th Consecutive Quarter

7 Best Stocks to Buy to Kick Off the New Year